As per MRFR analysis, the US Cell Harvesting Market Size was estimated at 1.62 (USD Billion) in 2023. The US Cell Harvesting Market Industry is expected to grow from 1.65(USD Billion) in 2024 to 4.19 (USD Billion) by 2035. The US Cell Harvesting Market CAGR (growth rate) is expected to be around 8.841% during the forecast period (2025 - 2035).
The US Cell Harvesting Market is experiencing significant growth driven by a rising demand for advanced therapeutic solutions and regenerative medicine. One of the key market drivers is the increasing adoption of cell and gene therapies, which require efficient and effective cell harvesting techniques. The surge in the prevalence of chronic diseases and the aging population in the US further fuels the need for innovative treatment options, thereby pushing the demand for cell harvesting technologies. Additionally, the push from federal agencies and private institutions toward research and clinical trials in regenerative medicine highlights the importance of cell harvesting in developing new therapies.
Opportunities for growth exist in the expansion of automated cell harvesting systems, which offer improved precision and efficiency compared to traditional methods. As the healthcare sector aims to optimize resources and reduce human error, these automated solutions present a viable avenue to capture a larger share of the market. Moreover, the integration of artificial intelligence and machine learning in cell harvesting processes can enhance data analysis and workflow optimization. In recent times, there has been a growing emphasis on personalized medicine in the US, which relates closely to cell harvesting. As healthcare providers prioritize tailored treatment plans, the ability to harvest and utilize patient-specific cells is becoming increasingly vital.
Furthermore, developments in cell banking and biopreservation techniques are creating new avenues for storing viable cells long-term, ensuring better accessibility for future medical applications. Overall, the US Cell Harvesting Market stands at a pivotal point, driven by technological advancements and shifting healthcare paradigms focused on innovative treatment options.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The rising incidence of cancer and other chronic diseases in the United States significantly drives growth in the US Cell Harvesting Market Industry. The American Cancer Society estimates that in 2023, there will be approximately 1.9 million new cancer cases diagnosed, highlighting a critical need for advanced treatment solutions. Furthermore, the National Health Institute indicates that the overall prevalence of chronic diseases, including diabetes and heart disease, has grown steadily, with projections of approximately 6 in 10 adults living with such conditions.
This growing patient population fueling a demand for cellular therapies and innovative treatment methods encourages the expansion of cell harvesting techniques, directly benefiting companies like Thermo Fisher Scientific and Beckman Coulter, which are leading the way in providing innovative harvesting solutions to meet the increasing demand.
Rapid advancements in technology within the field of cell harvesting are propelling growth in the US Cell Harvesting Market Industry. Innovations such as automated cell separation systems and novel biomaterials are improving efficiencies and lowering costs. A report from the National Institutes of Health suggests a 72% reduction in time required for cell sorting through new cell harvesting technologies compared to traditional methods.
Established organizations like Miltenyi Biotec and STEMCELL Technologies are driving these advancements, enabling healthcare providers in the US to adopt state-of-the-art harvesting methods, thereby expanding market opportunities.
The increasing investments in regenerative medicine significantly contribute to the growth of the US Cell Harvesting Market Industry. According to the National Institute of Health, regenerative medicine research funding has increased by over 158% in the past decade, with the US government and private entities allocating funds towards understanding stem cell applications.
Leading organizations like Osiris Therapeutics and Athersys are at the forefront of this investment, showcasing the demand for cell-based therapies that utilize harvested cells to repair or replace damaged tissues. This surge in financial support emphasizes the potential of cell harvesting in developing regenerative treatments, stimulating market growth.
The US Cell Harvesting Market is evolving significantly, driven by advancements in technology and increased demand for cell-based therapies. Within this market, the Product Type segmentation plays a critical role, particularly with Manual Cell Harvesters and Automated Cell Harvesters. Manual Cell Harvesters are widely utilized in laboratories, offering researchers the ability to perform precise and controlled cell extraction. This segment remains relevant, especially in the context of Research and Development activities, where customization and operator control are critical.
Automated Cell Harvesters, on the other hand, are gaining traction, owing to their efficiency, speed, and reproducibility. This technology significantly minimizes human error, contributes to a streamlined workflow, and can process a higher volume of samples with less operator input. The increasing trend toward automation, driven by the desire for greater consistency and higher throughput in cell isolation, indicates that Automated Cell Harvesters are likely to dominate the market given their ability to meet the demands of high-volume research and clinical applications.
Meanwhile, the potential for integration with other laboratory systems opens new opportunities for both segments, as organizations are increasingly looking to enhance productivity and data accuracy. Furthermore, the growing emphasis on precision medicine and cell therapies in the US healthcare landscape is amplifying the importance of effective cell harvesting methods. Overall, advances in technology within these product types are shaping the US Cell Harvesting Market, aligning it with the future of biomedical research and therapeutic development.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Cell Harvesting Market segmentation, particularly within the Application sector, is crucial for understanding the dynamics of this industry. The Biopharmaceutical Application plays a significant role, driven by the increasing demand for biologics and biosimilars in therapeutic developments. This application benefits from advanced harvesting techniques, improving the efficiency and yield of vital cell lines used in drug production.
Meanwhile, Stem Cell Research holds a prominent position, reflecting the growing interest in regenerative medicine and its applications in treating chronic diseases and injuries. The emphasis on stem cell therapy is surging, capturing the attention of researchers and healthcare professionals alike. In the US, government initiatives and funding for stem cell research contribute to its significance, ensuring ongoing advancements in treatment options. Overall, both applications are intertwined through innovation and necessity, each contributing to the substantial growth of the US Cell Harvesting Market industry. Market trends suggest that these applications are poised to thrive, supported by technological advancements and a robust research framework.
The End User segment of the US Cell Harvesting Market is significantly influenced by Pharmaceutical Companies, which play a pivotal role in the development of therapeutic products and drug discovery. These companies require efficient cell harvesting techniques to facilitate Research and Development processes, ensuring high quality and consistent yields for biopharmaceutical products. Given the ongoing advancements in regenerative medicine and cell-based therapies, Pharmaceutical Companies are increasingly adopting innovative cell harvesting technologies to meet their production demands and comply with stringent regulatory requirements.
The importance of this segment is highlighted by the rising investment in biotechnology, where tailored cell therapies and personalized medicine are becoming prevalent. These trends underscore the critical nature of cell harvesting services and technologies, as they directly impact the efficacy and safety of pharmaceutical products in the market. As the industry continues to evolve, Pharmaceutical Companies are anticipated to significantly shape the landscape of the US Cell Harvesting Market through their extensive research initiatives and the growing need for advanced therapeutic solutions.
The US Cell Harvesting Market is characterized by a diverse array of companies competing vigorously, as the demand for advanced cell-based therapies and regenerative medicine solutions grows. This competitive landscape is shaped by innovation, technological advancements, and strategic collaborations among the key players. Companies are investing significantly in research and development to enhance their product offerings and meet the evolving needs of healthcare providers and patients alike. The market is also influenced by regulatory frameworks that govern cell therapy practices, requiring companies to stay compliant while pursuing competitive advantages. As a result, businesses within the US Cell Harvesting Market continuously seek to improve their operational capabilities and expand their market share through effective marketing strategies and establishing strong relationships with customers and stakeholders.
Lonza Group stands out in the US Cell Harvesting Market due to its robust portfolio of products and services tailored for cell therapy applications. The company has established a significant presence with its innovative cell culture systems, bioprocessing technologies, and complementary services that cater to the growing demands of its clientele. Lonza's strength lies in its ability to provide comprehensive solutions ranging from cell line development to process optimization, which enhances the efficiency of cell harvesting and therapy production. Additionally, the company’s focus on maintaining high-quality standards and compliance with regulatory requirements has reinforced its reputation as a trusted partner within the market. Lonza's strong commitment to customer support and collaborative research initiatives further bolsters its competitive position, enabling it to meet the unique requirements of different stakeholders in the cell harvesting domain.
Terumo Corporation has made notable inroads in the US Cell Harvesting Market by offering a range of cutting-edge products and services that support the cell therapy industry's growth. The company's key offerings include specialized devices and solutions for effective cell collection, processing, and storage that align with the requirements of advanced therapeutic practices. Terumo's market presence is enhanced by its strategic partnerships and collaborations aimed at improving its technological capabilities and expanding its clientele. The company has continuously invested in innovation, evidenced by its consistent pipeline of new products that address specific challenges faced by healthcare providers. Additionally, Terumo has pursued mergers and acquisitions to enhance its market position and broaden its service portfolio. This proactive approach not only strengthens its operational capacity but also solidifies its role as a significant player in the US Cell Harvesting Market, catering to the diverse needs of customers while delivering reliable solutions in this dynamic field.
The US Cell Harvesting Market has seen significant developments recently, particularly with companies like Lonza Group, Terumo Corporation, and NantKwest. In October 2023, Merck KGaA announced a strategic partnership with Fujifilm Holdings Corporation aimed at enhancing cell therapy manufacturing, signaling an important collaboration in the sector. Meanwhile, in August 2023, Thermo Fisher Scientific reported impressive growth in their cell harvesting segment, reflecting a heightened demand for advanced cell-based therapies in the US.
In terms of market valuation, Beckman Coulter and Miltenyi Biotec also experienced notable growth attributed to increased investments and advancements in cell sorting technologies. Over the past couple of years, the expansion and refinement of cell harvesting techniques, evidenced by advancements made by GE Healthcare and STEMCELL Technologies, have significantly impacted the market landscape. Additionally, the ongoing innovations in cell-based therapies have necessitated improvements in manufacturing processes, driving competitiveness among companies in the sector. Changes in regulatory frameworks have also contributed to shaping the market, ensuring that quality and efficacy are maintained in the rapidly evolving landscape of cell harvesting technologies.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 1.62(USD Billion) |
| MARKET SIZE 2024 | 1.65(USD Billion) |
| MARKET SIZE 2035 | 4.19(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.841% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Lonza Group, Terumo Corporation, NantKwest, Paragon Bioservices, Cynata Therapeutics, Beckman Coulter, Thermo Fisher Scientific, Becton Dickinson and Company, Miltenyi Biotec, AllCells, Fujifilm Holdings Corporation, GE Healthcare, STEMCELL Technologies, Merck KGaA |
| SEGMENTS COVERED | Product Type, Application, End User |
| KEY MARKET OPPORTUNITIES | Advancements in cell isolation technologies, Growing demand for regenerative medicine, Increasing adoption of cell therapy, Rise in cancer research funding, Expansion of biobanking facilities |
| KEY MARKET DYNAMICS | increasing demand for regenerative medicine, advancements in cell extraction technologies, growing prevalence of chronic diseases, rising investments in biotechnology, stringent regulatory frameworks |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Cell Harvesting Market is expected to be valued at 1.65 billion USD in 2024.
By 2035, the overall market is projected to reach a value of 4.19 billion USD.
The market is expected to grow at a CAGR of 8.841 percent from 2025 to 2035.
The US Cell Harvesting Market is divided into Manual Cell Harvesters and Automated Cell Harvesters.
The market value for Manual Cell Harvesters is projected to be 1.63 billion USD by 2035.
Automated Cell Harvesters are expected to reach a market valuation of 2.56 billion USD by 2035.
Major players in the market include Lonza Group, Terumo Corporation, NantKwest, and Beckman Coulter, among others.
Factors driving the market include increasing demand for cell therapies and advancements in cell harvesting technologies.
Challenges include regulatory hurdles and the high cost of advanced harvesting equipment.
The current global scenario is influencing supply chains and investment trends within the US Cell Harvesting Market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
